חזרה לתוצאות החיפוש

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Major Depressive Disorder

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Neurocrine Clinical Site, Huntsville, Alabama, United States

  • Neurocrine Clinical Site, Bryant, Arkansas, United States

  • Neurocrine Clinical Site, Little Rock, Arkansas, United States

  • Neurocrine Clinical Site, Glendale, California, United States

  • Neurocrine Clinical Site, Los Angeles, California, United States

  • Neurocrine Clinical Site, Oceanside, California, United States

  • Neurocrine Clinical Site, Orange, California, United States

  • Neurocrine Clinical Site, Pico Rivera, California, United States

  • Neurocrine Clinical Site, San Diego, California, United States

  • Neurocrine Clinical Site, San Francisco, California, United States

  • Neurocrine Clinical Site, Upland, California, United States

  • Neurocrine Clinical Site, Cromwell, Connecticut, United States

  • Neurocrine Clinical Site, Farmington, Connecticut, United States

  • Neurocrine Clinical Site, Hollywood, Florida, United States

  • Neurocrine Clinical Site, Maitland, Florida, United States

  • Neurocrine Clinical Site, Maitland, Florida, United States

  • Neurocrine Clinical Site, Miami, Florida, United States

  • Neurocrine Clinical Site, Miami Gardens, Florida, United States

  • Neurocrine Clinical Site, Orlando, Florida, United States

  • Neurocrine Clinical Site, Palm Bay, Florida, United States

  • Neurocrine Clinical Site, Tampa, Florida, United States

  • Neurocrine Clinical Site, Tampa, Florida, United States

  • Neurocrine Clinical Site, Atlanta, Georgia, United States

  • Neurocrine Clinical Site, Gaithersburg, Maryland, United States

  • Neurocrine Clinical Site, Boston, Massachusetts, United States

  • Neurocrine Clinical Site, Watertown, Massachusetts, United States

  • Neurocrine Clinical Site, O'Fallon, Missouri, United States

  • Neurocrine Clinical Site, Saint Charles, Missouri, United States

  • Neurocrine Clinical Site, Cedarhurst, New York, United States

  • Neurocrine Clinical Site, Mount Kisco, New York, United States

  • Neurocrine Clinical Site, New York, New York, United States

  • Neurocrine Clinical Site, New York, New York, United States

  • Neurocrine Clinical Site, The Bronx, New York, United States

  • Neurocrine Clinical Site, Avon Lake, Ohio, United States

  • Neurocrine Clinical Site, Edmond, Oklahoma, United States

  • Neurocrine Clinical Site, Oklahoma City, Oklahoma, United States

  • Neurocrine Clinical Site, Philadelphia, Pennsylvania, United States

  • Neurocrine Clinical Site, Bellaire, Texas, United States

  • Neurocrine Clinical Site, Dallas, Texas, United States

  • Neurocrine Clinical Site, Houston, Texas, United States

  • Neurocrine Clinical Site, Richmond, Texas, United States

  • Neurocrine Clinical Site, Stafford, Texas, United States

  • Neurocrine Clinical Site, The Woodlands, Texas, United States

  • Neurocrine Clinical Site, Everett, Washington, United States

  • Neurocrine Clinical Site, Alken, Belgium

  • Neurocrine Clinical Site, Mechelen, Belgium

  • Neurocrine Clinical Site, Kardzhali, Bulgaria

  • Neurocrine Clinical Site, Plovdiv, Bulgaria

  • Neurocrine Clinical Site, Sofia, Bulgaria

  • Neurocrine Clinical Site, Sofia, Bulgaria

  • Neurocrine Clinical Site, Sofia, Bulgaria

  • Neurocrine Clinical Site, Sofia, Bulgaria

  • Neurocrine Clinical Site, Varna, Bulgaria

  • Neurocrine Clinical Site, Zagreb, Croatia

  • Neurocrine Clinical Site, Zagreb, Croatia

  • Neurocrine Clinical Site, Pilsen, Czechia

  • Neurocrine Clinical Site, Prague, Czechia

  • Neurocrine Clinical Site, Prague, Czechia

  • Neurocrine Clinical Site, Prague, Czechia

  • Neurocrine Clinical Site, Prague, Czechia

  • Neurocrine Clinical Site, Tallinn, Estonia

  • Neurocrine Clinical Site, Kuopio, Finland

  • Neurocrine Clinical Site, Oulu, Finland

  • Neurocrine Clinical Site, Tampere, Finland

  • Neurocrine Clinical Site, Budapest, Hungary

  • Neurocrine Clinical Site, Jelgava, Lativa, Latvia

  • Neurocrine Clinical Site, Liepāja, Lativa, Latvia

  • Neurocrine, Sigulda, Lativa, Latvia

  • Neurocrine Clinical Site, Jelgava, Latvia

  • Neurocrine Clinical Site, Liepāja, Latvia

  • Neurocrine Clinical Site, Kaunas, Lithuania

  • Neurocrine Clinical Site, Amsterdam, Netherlands

  • Neurocrine Clinical Site, Groningen, Netherlands

  • Neurocrine Clinical Site, Leiden, Netherlands

  • Neurocrine Clinical Site, Bełchatów, Poland

  • Neurocrine Clinical Site, Bialystok, Poland

  • Neurocrine Clinical Site, Bialystok, Poland

  • Neurocrine Clinical Site, Bialystok, Poland

  • Neurocrine Clinical Site, Bydgoszcz, Poland

  • Neurocrine Clinical Site, Gdansk, Poland

  • Neurocrine Clinical Site, Gdansk, Poland

  • Neurocrine Clinical Site, Grudziądz, Poland

  • Neurocrine Clinical Site, Katowice, Poland

  • Neurocrine Clinical Site, Craiova, Romania

  • Neurocrine Clinical Site, Bojnice, Slovakia

  • Neurocrine Clinical Site, Bratislava, Slovakia

  • Neurocrine Clinical Site, Košice, Slovakia

  • Neurocrine Clinical Site, Rimavská Sobota, Slovakia

  • Neurocrine Clinical Site, Svidník, Slovakia

  • Neurocrine Clinical Site, Vranov nad Topľou, Slovakia

  • Neurocrine Clinical Site, Gothenburg, Sweden

  • Neurocrine Clinical Site, Lund, Sweden

  • Neurocrine Clinical Site, Stockholm, Sweden

  • Neurocrine Clinical Site, Taipei, Taiwan

  • Neurocrine Clinical Site, Southampton, Hampshire, United Kingdom

  • Neurocrine Clinical Site, Sheffield, South Yorkshire, United Kingdom

  • Neurocrine Clinical Site, London, United Kingdom

  • Neurocrine Clinical Site, Manchester, United Kingdom

מובילי המחקר

  • Clinical Development Lead

    Study Director

    Neurocrine Biosciences

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)